24th August 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Novartis plans to eliminate many leadership positions in Switzerland as part of 1,400 layoffs

Now comes word that more leaders may be on their way out. Up to half of the 1,400 jobs that the pharmaceutical giant intends to eliminate in Switzerland will be in positions of leadership.

USFDA approves of Unichem's generic medication

The anticonvulsant medication Carbamazepine Tablets, with a 200 mg strength, have been approved for sale in the US market, according to drug company Unichem Laboratories.

Regardless of Prior Dengue Exposure, Takeda's QDENGA Approved for Use in Indonesia

Indonesia National Agency for Drug and Food Control has given its approval to Takeda’s QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003 dengue vaccine).

Pharma industry anticipates FY23 revenue growth of 7-9 percent

According to CRISIL, new product launches and a 6–8% average price increase permitted by the National Pharmaceutical Pricing Authority in March 2022 are expected to drive the domestic formulations market’s 7-9% growth this fiscal year, up from 15% growth last year.

Merck's investigational anticoagulant therapy receives fast track designation from USFDA

USFDA has given Merck’s investigational anticoagulant therapy MK-2060 Fast Track designation in order to lower the risk of major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD).

Alcon, a Swiss eye-care company, to acquire Aerie Pharma for approximately $753 million

As the Swiss eye-care company looks to expand its pipeline of optical treatments, Alcon AG announced that it would buy Aerie Pharmaceuticals in a deal estimated to be worth $753 million.

Pfizer & BioNTech request US FDA emergency use authorization for Covid-19 vaccine

Pfizer Inc. and BioNTech SE announced that they have completed a submission to the USFDA requesting an Emergency Use Authorization for a booster dose of an Omicron BA.4/BA.5 adapted bivalent Covid-19 vaccine for people aged 12 and older.

Update profile

Please update your profile to keep using the website

Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?